Regulatory Submission

REGENXBIO clears dosing hurdle, sets up Q3 BLA for DMD gene therapy RGX-202

REGENXBIO finished dosing its confirmatory study ahead of schedule after RGX-202 hit its microdystrophin biomarker target in the pivotal cohort, teeing up an accelerated-approval filing built on a surrogate endpoint.

By AppliedXLJuly 13, 2026Trial NCT05693142

Executive Summary

REGENXBIO finished dosing patients in the confirmatory portion of its Duchenne muscular dystrophy gene therapy program ahead of its own timeline, clearing the way for a BLA filing under the accelerated approval pathway.
The filing leans on a biomarker surrogate that the pivotal study hit at a high rate, paired with a functional dataset that remains thin at the 12-month mark, a split that will shape how the FDA and the market weigh the case.
RGX-202 enters a Duchenne gene therapy field that already has one approved microdystrophin product and multiple later-stage rivals, so the differentiation question is about dose, durability, and safety, not about being first.
The accelerated approval pathway obligates REGENXBIO to a confirmatory trial regardless of the BLA outcome, meaning even a positive filing decision defers the definitive functional-benefit answer.

The milestone

REGENXBIO said on June 24, 2026 that it completed dosing in the confirmatory study of RGX-202 ahead of schedule, citing patient demand and investigator interest, and confirmed it remains on track to submit a BLA in the third quarter of 2026 for a potential FDA decision in the second half of 2027. The submission will draw on a safety dataset spanning both the pivotal and confirmatory studies, 63 patients combined, and efficacy data from the 30-patient pivotal portion. RGX-202 is dosed intravenously and studied under NCT05693142, the AFFINITY DUCHENNE trial, in ambulatory boys with DMD gene mutations in exon 18 and beyond. REGENXBIO+1

Probability of Success

Endpoint Met24%

Completes48%

Clinical Significance50%

Regulatory59%

The result behind the filing

In the pivotal dataset, RGX-202 met its primary endpoint, at least 10% microdystrophin expression, in more than 93% of patients at Week 12. Chief Executive Officer Curran Simpson said the dataset "directly aligns with the established accelerated approval criteria: the magnitude of clinical effect seen in functional improvement from baseline, correlation between the biomarker and functional outcomes, and a differentiated safety profile". Functional data from patients who reached the 12-month assessment, a group of 9, showed improvement on timed function tests and the North Star Ambulatory Assessment, and the company reported a favorable safety profile with no additional detail on adverse event rates. REGENXBIO

The pathway's built-in obligation

The FDA aligned with REGENXBIO on accelerated approval access for the AFFINITY DUCHENNE program in November 2024, before this filing milestone. RGX-202 also holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations, signals of the unmet need in Duchenne but not predictors of approval on their own. Accelerated approval based on the microdystrophin surrogate carries a mandatory confirmatory trial requirement, and the FDA can withdraw the approval if that trial fails to confirm clinical benefit. REGENXBIO

Where it sits in the field

Duchenne gene therapy already has an approved microdystrophin entrant from Sarepta Therapeutics, and Solid Biosciences has advanced a competing microdystrophin construct into Phase 3 testing, alongside an RNA-based Phase 1/2 program from Dyne Therapeutics. Against that field, RGX-202's differentiation case rests on dose level and construct design, including a C-terminal domain the company says other microdystrophin constructs lack, and on the safety and durability data the confirmatory study will eventually generate. REGENXBIO

Registry context

The trial's registry record shows two enrollment revisions, from 18 to 15 patients in July 2024, then to 65 patients in January 2025, alongside a primary completion date shift from December 2025 to February 2026. The current registry primary completion date of December 1, 2025 predates the company's own guided BLA filing window of July through September 2026, a gap that reflects the registry entry not yet catching up to the confirmatory study's completed dosing REGENXBIO just announced. NCT05693142

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.